Skip to main content

Table 1 Generalities and patients baseline of the included studies

From: Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis

Author, year Journal Follow-up (months) Calcium daily supplement (mg) Vit D daily supplement (UI) Treatment Administration Samples (n) Mean age Mean BMI (kg/m2) BMD
Spine (g/cm2)
BMD
Hip
(g/cm2)
BMD
Femur neck (g/cm2)
Anastasilakis et al. 2015 [29] Osteoporos Int 12 1000 800 Denosumab IM 32 63 28.80 0.97   
Zoledronate IV 26 63 28.70 0.94   
Placebo IV 241 57 23.73 0.92 0.65 0.63
Black et al. 2007 [30] New England J Med 36 1000-1500 400-1200 Zoledronate IV 3875 73 25.10 0.79 0.65 0.53
Placebo IV 3861 73 25.40 0.79 0.65 0.53
Body et al. 2002 [31] J Clin Endocrinol Metab 14 1000 400-1200 Alendronate OS 73 65 24.40 0.80   
Teriparatide SC 73 66 23.90 0.80   
Black et al. 1996 [32] The Lancet 36 652   Alendronate OS 1022 71 25.50 0.79   0.57
619   Placebo OS 1005 71 25.60 0.79   0.56
Black et al. 2006 [33] JAMA 60 655   Alendronate OS 329 73 25.70 0.90 0.73 0.62
667   Alendronate OS 333 73 25.90 0.89 0.73 0.61
635   Placebo OS 437 74 25.80 0.90 0.72 0.61
Black et al. 2012 [34] J Bone Min Res 36 1000-1500 400-1200 Zoledronate IV 616 76 25.30 0.81 0.69 0.56
Placebo IV 617 76 25.60 0.82 0.69 0.57
Black et al. 2015 [35] J Bone Min Res 36 1000-1500 400-1200 Zoledronate IV 95 78 24.60   0.69 0.58
Placebo IV 95 78 25.00   0.71 0.58
Bone et al. 1997 [36] J Clin Endocrinol Metab 24 813   Alendronate OS 86 71     
880   Alendronate OS 89 70     
831   Alendronate OS 93 71     
900   Placebo OS 91 71     
Brown et al. 2014 [37] Osteoporos Int 12    Denosumab SC 852 68     
   Ibandronate OS 851 67     
   Risedronate OS     
Brumsen et al. 2002 [38] J Bone Min Res 60 500 400 Pamidronate OS 26 66   0.76   0.64
Placebo OS 27 64   0.74   0.64
Chesnut et al. 2004 [39] J Bone Min Res 36 500 400 Ibandronate OS 977 69 26.20    
Ibandronate OS 977 69 26.20    
Placebo OS 975 69 26.20    
Clemmesen et al. 1997 [40] Osteoporos Int 36 1000   Risedronate OS 44 67 25.50 0.80   0.61
  Risedronate/placebo OS 44 68 24.40 0.79   0.61
  Placebo OS 44 70 25.10 0.75   0.61
Cosman et al. 2016 [10] New England J Med 12 500-1000 600-800 Romosozumab SC 3589 71     
Placebo SC 3591 71     
24 500-1000 600-800 Denosumab SC 3589 71     
Denosumab SC 3591 71     
Cummings et al. 1998 [41] JAMA 48 634   Alendronate OS 2214 68 24.90 0.84   0.59
638   Placebo OS 2218 68 25.00 0.84   0.59
Cummings et al. 2009 [42] New England J Med 36 1000 400-800 Denosumab SC 3902 72 26.00    
Placebo SC 3906 72 26.00    
Delmas et al. 2002 [43] J Clin Endocrinol Metab 48 500 400-600 Raloxifene OS 2259 66 25.30 0.82   0.62
Raloxifene OS 2277 66 25.20 0.81   0.62
Placebo OS 2292 67 25.30 0.81   0.62
Ettinger et al. 1999 [7] JAMA 36 500 400-600 Raloxifene OS 2259 67     
Raloxifene OS 2277  
Placebo OS 2292     
Fogelman et al. 2000 [44] J Clin Endocrinol Metab 24 1000   Risedronate OS 184 65 24.80 0.73   0.63
  Risedronate OS 177 65 24.80 0.75   0.64
   Placebo OS 180 64 25.50 0.74   0.64
Frediani et al. 1998 [45] Clin Drug Invest 24    Alendronate OS 30 63 20.90 0.81   
   Calcitriol OS 30 63 21.80 0.81   
   Alendronate/calcitriol OS 30 63 21.00 0.80   
   Calcium OS 30 63 21.20 0.80   
Garg et al. 2015 [46] J South Asian Feder Menopause
Soc
12    Zoledronate IV 50      
   Teriparatide SC 50      
Gonnelli et al. 2014 [47] Bone 12 841 400 Zoledronate IV 30 66 26.10 0.82 0.79  
  870   Ibandronate IV 30 67 25.70 0.82 0.79  
Greenspan et al. 2015 [48] JAMA 24 807 163 Zoledronate IV 89 85 28.20 0.93 0.68 0.61
763 168 Placebo IV 92 86 26.90 0.97 0.70 0.62
Grey et al. 2009 [49] J Clin Endocrinol Metab 24 935   Zoledronate IV 25 62   1.06 0.85  
916   Placebo IV 25 65   1.03 0.86  
Grey et al. 2012 [50] J Clin Endocrinol Metab 12 960   Zoledronate IV 43 64   1.01 0.85  
880   Zoledronate IV 43 66   1.03 0.84  
850   Zoledronate IV 43 66   1.05 0.84  
950   Placebo IV 43 65   1.03 0.87  
Guanabens et al. 2013 [51] Hepatology 24 1000   Ibandronate OS 14 65 26.60 0.90 0.84 0.79
  Alendronate OS 19 63 26.60 0.88 0.81 0.77
Harris et al. 1993 [52] Am J Med 48 500   Phosphate-etidronate OS 63    0.89   0.67
  Placebo-etidronate OS 65    0.87   0.69
  Phosphate-placebo OS 62    0.87   0.67
  Placebo OS 63    0.86   0.68
Harris et al. 1999 [53] JAMA 36 1000 500 Risedronate OS 817 69 26.60 0.84   0.60
Risedronate OS 821 69 26.60 0.83   0.59
Placebo OS 820 68 26.50 0.83   0.60
Hooper et al. 2005 [54] Climacteric 24    Risedronate 1OS 128 53   1.08   
   Risedronate OS 129 53   1.08   
   Placebo OD 126 53   1.08   
Iwamoto et al. 2008 [55] Yonsei Med J 12 800   Alendronate OS 61 70 21.90 0.62   
  Raloxifene OS 61 69 21.70 0.65   
Kendler et al. 2019 [56] Osteoporosis Int 12 > 1000 > 800 Romosozumab SC 16 69     
Romosozumab SC 19 68     
Romosozumab SC 14      
Romosozumab SC 12      
Langdahl et al. 2017 [57] The Lancet 12 500-1000 600-800 Romosozumab SC 198 72     
Teriparatide SC 200 71     
Leder et al. 2015 [58] The Lancet 48    Teriparatide-denosumab SC 27 66 25.50 0.82   0.64
   Denosumab-teriparatide SC 27 65 23.80 0.86   0.64
   Combined-denosumab SC 23 65 25.90 0.85   0.64
Leder et al. 2014 [59] J Clin Endocrinol Metab 24    Teriparatide SC 31 66 25.50 0.82   0.64
   Denosumab SC 33 66 24.10 0.87   0.64
   Combined SC 30 66 25.40 0.86   0.64
Lewiecki et al. 2018 [60] J Clin Endocrinol Metab 12    Denosumab SC 3003 71 24.70    
   Denosumab SC 3042 71 24.70    
Liang et al. 2017 [61] Orthop Surg 24    Zoledronate IV 155 57 21.80 0.63 0.75  
   Placebo IV 95 57 21.60 0.63 0.75  
   Placebo OS 355 64 24.10    
Lufkin et al. 1998 [62] J Bone Min Res 12    Raloxifene OS 48 67 24.80 0.75 0.64  
   Raloxifene OS 47 67 26.20 0.81 0.69  
750 400 Calcium/vit D OS 48 68 25.30 0.77 0.67  
Lyritis et al. 1997 [63] Clin Rheumatol 48 500   Etidronate OS 39 72 27.60 0.57   0.42
   Calcium/vit D OS 35 72 26.80 0.57   0.43
McClung et al. 2014 [64] New England J Med 12 1000 800 Romosozumab SC 44 67     
Romosozumab SC 46 67     
Romosozumab SC 49 67     
Romosozumab SC 52 67     
Romosozumab SC 53 67     
Alendronate OS 47 67     
Teriparatide SC 46 67     
Placebo SC 47 67     
McClung et al. 2009 [65] ObstetGynecol 24 500-1200 400-800 Zoledronate IV 181 60 26.50 0.86   0.69
Zoledronate-placebo IV 154 60 27.30 0.86   0.69
Placebo IV 188 61 27.20 0.86   0.69
McClung et al. 2018 [66] J Bone Min Res 12 1000 800 Denosumab SC 127 67     
Placebo SC 131 67     
Meunier et al. 2004 [67] New England J Med 36 1000 400-800 Strontium ranelate OS 719 69 26.20 0.73 0.69 0.59
Placebo OS 723 69 26.20 0.72 0.68 0.59
Meunier et al. 2009 [68] Osteoporos Int 12 1000 400-800 Strontium ranelate OS 221 72   0.85   0.66
Strontium ranelate OS 434 72   0.72   0.58
Placebo OS 225 72   0.86   0.64
Miller et al. 2016 [69] J Clin Endocrinol Metab 12 1000 800 Denosumab SC 321 69 24.30    
Zoledronate IV 322 70 24.30    
Miyauchi et al. 2019 [68] Arch Osteoporos 36 500-1000 600-800 Denosumab SC 247 71 21.10    
Denosumab SC 245 70 21.40    
Montessori et al. 1997 [70] Osteoporos Int 36    Etidronate OS 40 62   0.68 0.67 0.60
   Calcium OS 40 63   0.67 0.69 0.61
Morii et al. 2003 [71] Osteoporos Int 13    Raloxifene OS 90 65 21.50 0.66   
   Raloxifene OS 93 65 21.90 0.67   
   Placebo OS 97 64 22.00 0.64   
Mortensen et al. 1998 [72] J Clin Endocrinol Metab 36 937   Risedronate OS 37 52   0.93   0.74
1057   Risedronate OS 38 51   0.93   0.71
936   Placebo OS 36 51   0.96   0.74
Neer et al. 2001 [73] New England J Med 24 1000 400-1200 Teriparatide SC 444 69   0.82 0.70 0.64
Teriparatide SC 434 70   0.82 0.70 0.64
Placebo SC 448 69   0.82 0.71 0.64
Paggiosi et al. 2014 [74] Osteoporos Int 24 1200 800 Alendronate OS 57 68 25.90 0.79 0.75 0.64
Ibandronate OS 58 67 26.40 0.80 0.78 0.64
Risedronate OS 57 67 26.80 0.81 0.80 0.67
Control   226 38 25.10 1.,07 0.97 0.86
Papapoulos et al. 2012 [75] J Bone Min Res 24    Denosumab SC 2343 75     
   Denosumab SC 2207 75     
Papapoulos et al. 2015 [76] Osteoporos Int 60 > 1000 > 400 Denosumab SC 2343 79     
Denosumab SC 2207 79     
Popp e t al. 2013 [77] Maturitas 36 1000-1500 400-1200 Zoledronate IV 55 77 24.60 0.77 0.67 0.56
Placebo IV 55 77 24.40 0.77 0.67 0.55
Recknor et al. 2013 [26] ObstetGynecol 12 500 800 Denosumab SC 417 67 25.50    
   Ibandronate OS 416 66 25.10    
Reginster et al. 2009 [78] Osteoporos Int 36 500-1000 400-800 Strontium ranelate OS 879 79 25.90 0.93 0.73 0.61
Control OS 892 74 25.90 0.77 0.67 0.57
Reginster et al. 2011 [79] Osteoporos Int 60 500-1000 400-800 Strontium ranelate OS 233 77 25.80 0.76 0.69 0.58
Placebo OS 458 76 25.20    
Roux et al. 2014 [80] Bone 12 ≥ 1000 ≥ 800 Denosumab SC 435 68     
Risedronate OS 435 68     
Saag et al. 2017 [11] New England J Med 24    Alendronate OS 2047 74 25.40    
   Romosozumab-alendronate SC-OS 2046 74 25.50    
Tsai et al. 2013 [81] The Lancet 12    Teriparatide SC 31 66 25.50 0.82 0.76 0.64
   Denosumab SC 33 66 24.10 0.87 0.77 0.64
   Teriparatide/denosumab SC 30 66 25.40 0.86 0.76 0.64
Tsai et al. 2019 [82] The Lancet 15    Teriparatide-denosumab SC 35 66 23.00 0.83 0.74 0.65
   Teriparatide-denosumab SC 34 67 22.80 0.79 0.74 0.62
Tucci et al. 1996 [83] Am J Med 36 500   Alendronate OS 98 67 23.90    
  Alendronate OS 94 64 23.30    
  Alendronate OS 94 64 23.70    
  Placebo OS 192 64 23.80    
Jiang et al. 2003 [84] J Bone Min Res 19 1000 400-1200 Teriparatide SC 18 68   0.77   0.61
Teriparatide SC 14 68   0.84   0.62
Placebo SC 19 68   0.86   0.65